ANPCY News and Press, Angle Plc Surrey ADR From 09/13/19

PUBLICATION ON USE OF PARSORTIX IN HEAD AND NECK CANCER Opportunity for Parsortix to be used for PD-L1 analysis of CTCs to assess whether patients will benefit from immunotherapies GUILDFORD, SURREY / ACCESSWIRE / September 13, 2019 / ANGLE plc (AIM:AGL OTCQX:ANPC...

BREAKTHROUGH RESEARCH DEMONSTRATES A PARSORTIX TEST COULD AVOID UNNECESSARY PROSTATE BIOPSIES Barts Cancer Institute demonstrates capability of Parsortix system to detect clinically significant prostate cancer to reduce over-diagnosis and over-treatment Results published in peer...

ANGLE plc ("the Company") MEDICAL UNIVERSITY OF VIENNA DEMONSTRATES USE OF PARSORTIX FOR NEUROENDOCRINE ANALYSIS IN SMALL CELL LUNG CANCER Neuroendocrine markers on CTCs associated with poor overall survival Potential for faster diagnosis, patient stratification and on...

INITIATION OF OVARIAN CANCER CLINICAL VERIFICATION STUDY First patient enrolled, targeted completion of study in Q1 CY20 GUILDFORD, SURREY / ACCESSWIRE / August 29, 2019 / ANGLE plc (AIM:AGL) OTCQX:ANPCY), a world-leading liquid biopsy company, ...

BUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET FDA SUBMISSION ON TRACK FOLLOWING POSITIVE RESULTS FROM BREAST CANCER CLINICAL STUDY GUILDFORD, SURREY / ACCESSWIRE / July 31, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy compan...

ANGLE plc ("the Company") LEADING CUSTOMER DEMONSTRATES USE OF PARSORTIX FOR SINGLE CELL ANALYSIS OF CIRCULATING TUMOR CELLS Measurement of gene expression shows heterogeneity between cancer cells and may help guide treatment in the future ...

GUILDFORD, SURREY / ACCESSWIRE / June 28, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 30 April 2019 on Wednesday 31 July 2019. A meeting for analysts will be held at 10:30am on 31 July 2019 at ...

Leading Cancer Centre Demonstrates Use of Parsortix as a Liquid Biopsy to Investigate Key Immunotherapy Target in Lung Cancer Potential for use of Parsortix as treatment selection biomarker in assessing patient response to cancer immunotherapy drugs with revenues forecast to exceed US$ 20...

ANGLE plc ("the Company") SUCCESSFUL COMPLETION OF OVARIAN CANCER PRE-STUDY Pre-study demonstrates ANGLE's optimised sample-to-answer molecular solution with patient samples GUILDFORD, SURREY / ACCESSWIRE / June 5, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liqu...

Analytical studies ongoing to support FDA submission GUILDFORD, SURREY / ACCESSWIRE / May 31, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from its Parsortix FDA clinical study for metastatic breast cancer. T...